Humacyte, Inc. (NASDAQ:HUMA) Shares Sold by GSA Capital Partners LLP

GSA Capital Partners LLP trimmed its position in Humacyte, Inc. (NASDAQ:HUMA) by 46.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 120,318 shares of the company’s stock after selling 103,861 shares during the period. GSA Capital Partners LLP owned about 0.10% of Humacyte worth $655,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. nVerses Capital LLC acquired a new stake in Humacyte in the 2nd quarter worth about $28,000. Concurrent Investment Advisors LLC acquired a new stake in Humacyte in the 3rd quarter worth about $75,000. Principal Financial Group Inc. acquired a new stake in Humacyte in the 2nd quarter worth about $83,000. Profund Advisors LLC acquired a new stake in Humacyte in the 2nd quarter worth about $97,000. Finally, XTX Topco Ltd acquired a new stake in Humacyte in the 2nd quarter worth about $110,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on HUMA. TD Cowen restated a “buy” rating and set a $10.00 target price on shares of Humacyte in a report on Friday, October 18th. Cantor Fitzgerald restated an “overweight” rating and set a $13.00 target price on shares of Humacyte in a report on Friday, September 20th. Benchmark restated a “buy” rating and set a $15.00 target price on shares of Humacyte in a report on Thursday, October 10th. EF Hutton Acquisition Co. I upgraded Humacyte to a “strong-buy” rating in a report on Monday, September 9th. Finally, HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Humacyte in a report on Wednesday, November 13th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $11.00.

Humacyte Stock Down 8.1 %

HUMA stock opened at $4.45 on Tuesday. The firm has a market cap of $530.51 million, a PE ratio of -3.35 and a beta of 1.47. The company has a debt-to-equity ratio of 0.61, a quick ratio of 5.41 and a current ratio of 1.10. The firm’s 50 day moving average price is $5.42 and its 200-day moving average price is $6.20. Humacyte, Inc. has a one year low of $2.43 and a one year high of $9.97.

Insider Activity

In other Humacyte news, CEO Laura E. Niklason sold 277,090 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $6.47, for a total value of $1,792,772.30. Following the sale, the chief executive officer now owns 4,029,374 shares of the company’s stock, valued at $26,070,049.78. The trade was a 6.43 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Brady W. Dougan sold 252,676 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total value of $1,695,455.96. Following the completion of the sale, the director now directly owns 4,306,464 shares in the company, valued at approximately $28,896,373.44. The trade was a 5.54 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,084,153 shares of company stock valued at $6,869,996. 11.20% of the stock is currently owned by company insiders.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.